Payment overview · 2025
General Payments
$403.47
21 reported records · 9 companies
Healthcare provider profile · identity verified
Jeffrey Peterman, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · SAULT SAINTE MARIE, MI · NPI 1184712432
Verified facts
What the public records show
CMS Open Payments records show Jeffrey Peterman, M.D. received $403.47 in general payments during 2025 across 21 reported records.
Amgen Inc. accounted for 49.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Enbrel by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $198.17 | 49.1% | 11 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $49.24 | 12.2% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $47.61 | 11.8% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.73 | 5.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.34 | 5.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $18.44 | 4.6% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.80 | 4.4% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $16.07 | 4.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.07 | 3.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $403.47 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $172.05 | 9 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $49.24 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $47.61 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $26.12 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $26.12 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.73 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $20.34 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $18.44 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.80 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.07 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.07 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 88 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 13 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
88 | 19 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 12 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
40 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 346 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 340 | 74 |
| Celecoxib | Celecoxib | 299 | 67 |
| Atorvastatin Calcium | Atorvastatin Calcium | 295 | 77 |
| Amlodipine Besylate | Amlodipine Besylate | 268 | 64 |
| Omeprazole | Omeprazole | 259 | 58 |
| Losartan Potassium | Losartan Potassium | 229 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 214 | 42 |
| Meloxicam | Meloxicam | 190 | 38 |
| Simvastatin | Simvastatin | 189 | 42 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 185 | 45 |
| Lisinopril | Lisinopril | 184 | 39 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 184 | 43 |
| Gabapentin | Gabapentin | 181 | 42 |
| Tamsulosin Hcl | Tamsulosin Hcl | 181 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 172 | 49 |
| Duloxetine Hcl | Duloxetine Hcl | 171 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 169 | 28 |
| Buprenorphine | Buprenorphine | 161 | 23 |
| Tramadol Hcl | Tramadol Hcl | 160 | 40 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 149 | 24 |
| Furosemide | Furosemide | 146 | 30 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 132 | 22 |
| Trazodone Hcl | Trazodone Hcl | 125 | 22 |
| Prazosin Hcl | Prazosin Hcl | 123 | 22 |
| Metformin Hcl | Metformin Hcl | 121 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 117 | 30 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 114 | 21 |
| Ezetimibe | Ezetimibe | 112 | 26 |
| Xarelto | Rivaroxaban | 106 | 18 |
| Allopurinol | Allopurinol | 104 | 27 |
| Topiramate | Topiramate | 104 | 18 |
| Olanzapine | Olanzapine | 102 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 101 | 23 |
| Buspirone Hcl | Buspirone Hcl | 98 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 97 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 93 | 26 |
| Valsartan | Valsartan | 92 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 91 | 21 |
| Jardiance | Empagliflozin | 88 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 85 | 14 |
| Carvedilol | Carvedilol | 82 | 16 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 82 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 82 | 23 |
| Lorazepam | Lorazepam | 81 | 17 |
| Donepezil Hcl | Donepezil Hcl | 77 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 72 | 15 |
| Baclofen | Baclofen | 72 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 70 | 15 |
| Ozempic | Semaglutide | 68 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 68 | 17 |
| Sertraline Hcl | Sertraline Hcl | 67 | 17 |
| Estradiol | Estradiol | 64 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 64 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 61 | 14 |
| Entresto | Sacubitril/Valsartan | 57 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 55 | 13 |
| Farxiga | Dapagliflozin Propanediol | 55 | 13 |
| Pregabalin | Pregabalin | 55 | suppressed |
| Myrbetriq | Mirabegron | 52 | 12 |
| Morphine Sulfate Er | Morphine Sulfate | 50 | suppressed |
| Potassium Chloride | Potassium Chloride | 50 | 11 |
| Prednisone | Prednisone | 50 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 48 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 45 | suppressed |
| Atenolol | Atenolol | 44 | 11 |
| Mirtazapine | Mirtazapine | 42 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 41 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 41 | 35 |
| Eliquis | Apixaban | 40 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 36 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 23 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Spironolactone | Spironolactone | 35 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Fentanyl | Fentanyl | 34 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 32 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 15 |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Gemfibrozil | Gemfibrozil | 29 | suppressed |
| Risperidone | Risperidone | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | 11 |
| Primidone | Primidone | 27 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 26 | suppressed |
| Nystatin | Nystatin | 25 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 25 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 15 |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 24 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 24 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 23 | suppressed |
| Roflumilast | Roflumilast | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Clarithromycin | Clarithromycin | 21 | 20 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 14 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Lamotrigine | Lamotrigine | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 19 |
| Ondansetron Odt | Ondansetron | 20 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Trulicity | Dulaglutide | 18 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 11 |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Lidocaine | Lidocaine | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Famotidine | Famotidine | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 12 | suppressed |
| Mitigare | Colchicine | 12 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 12 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 12 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Enbrel | Etanercept | 11 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 11 | suppressed |
| Invokana | Canagliflozin | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 11 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
| Triumeq | Abacavir/Dolutegravir/Lamivudi | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $403.47 · 21 records | Amgen Inc. | Auvelity, BREZTRI, CAPLYTA, JARDIANCE, KRYSTEXXA, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Rybelsus, TRELEGY ELLIPTA, VRAYLAR, ZAVZPRET | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error